Literature DB >> 32723344

COVID-19: not a contraindication for surgery in patients with proximal femur fragility fractures.

Ilaria Morelli1, Francesco Luceri2, Riccardo Giorgino1, Riccardo Accetta3, Paolo Perazzo4, Laura Mangiavini2,5, Nicola Maffulli6,7,8, Giuseppe M Peretti2,5.   

Abstract

Entities:  

Keywords:  COVID-19; Fragility fractures; Prognosis; Proximal femur fractures; Surgical treatment

Mesh:

Year:  2020        PMID: 32723344      PMCID: PMC7385330          DOI: 10.1186/s13018-020-01800-9

Source DB:  PubMed          Journal:  J Orthop Surg Res        ISSN: 1749-799X            Impact factor:   2.359


× No keyword cloud information.
During the SARS-CoV-2 outbreak, Italy was the leading country for the number of new positive cases from March 8 2020, to March 21, and the first for the total number of deaths from March 19, to April 12 2020 [1-4]. The Italian National Healthcare System required the conversion of many wards into COVID-19 care units, and the suspension of deferrable treatments, surgical procedures and outpatient visits, to dedicate human and material resources to free Intensive Care Unit (ICU) beds. In the most struck regions, some hospitals were designated as hubs for non-delayable treatments [5, 6]. Our institution (IRCCS Orthopaedic Institute Galeazzi) was chosen amongst the Trauma Hubs. Orthopaedic trauma surgery focused mainly on femoral fragility fractures in the elderly, since the “lockdown” began on March 10, 2020. Proximal femur fractures carry a high mortality rate [7], and the standard of care involves surgery within 48 h from the trauma [8]. These elderly patients are also the most susceptible to the nefarious consequences of COVID-19 [9]. Thus, orthopaedic surgeons face the daily dilemma of performing life-saving surgery on patients who, given their severe respiratory compromise, have a higher risk of peri-operative death. Preliminary reports from Wuhan, Bergamo (the Italian province with the highest number of cases) and Spain drew different conclusions on the possible benefit effects of surgery on COVID-19 patients with proximal femur fractures [10-12]. In the first case series, six patients reported proximal femur fractures, but only three were considered eligible for surgery because of no signs of pneumonia at CT scan or non-severe respiratory symptoms [10]. Three of them died, two after conservative management. Of the three surviving patients, two underwent surgery: the authors concluded that patients with proximal femoral fractures and COVID-19 have a higher risk of death. In a series of 16 such patients in Bergamo (Lombardy), Italy [11], three patients died before surgeries for respiratory failure. The other 13 patients (temperature < 38 °C, pO2 > 90% and no signs of multiorgan dysfunction) underwent surgery, with four dying in the first postoperative week. Oxygen saturation improved after surgery in the survivors. Finally, a multicentre observational study on 136 proximal femoral fractures reported an overall 30.4% mortality in COVID-19 patients. The mortality rate was 67% in COVID-19 patients treated non-operatively, and only 4% in patients who underwent surgery [12]. The early outcomes (March 17–April 17, 2020) from our Trauma hub endorse the “to fix” faction. Ten swab-confirmed COVID-19 patients (8 women and 2 men) with a mean age of 83.9 ± 7.4 years (range 72-98) underwent surgical treatment for their proximal femoral fractures within 48 h from admission at our facility: 8 patients received intramedullary nailing for AO 31A fractures, and 2 received hemiarthroplasty for AO 31B fractures [13]. The mean oxygen saturation on admission was 94.4% (range 90-97), breathing ambient air by 9 patients and 4 litres/minute oxygen through Venturi mask by 1 patient. In 6 patients, atypical pneumonia was evident on plain chest radiographs on admission. Three patients underwent a further plain chest radiograph after surgery (one showed improvement, one a stable pulmonary involvement and in one patient the pneumonia worsened). Four patients developed systemic complications, including respiratory failure as reported in Table 1. Only two of these patients died, both 8 days after surgery: one of them had pneumonia on plain chest radiographs on admission. Both these patients presented the lowest oxygen saturation breathing ambient air on admission (93% and 90%, respectively). The mean length of stay in the Trauma Unit was 12.9 ± 6.9 days (range 7-29), and the surviving patients were finally discharged to our in-hospital rehabilitation unit with an improved or stable oxygen saturation, with 7 of the 8 surviving patients needing no further oxygen support.
Table 1

Patients’ demographics, comorbidities, surgical and clinical details, respiratory parameters and need of oxygen support

Case n°12345678910
SexFFMFFFFFFM
Age85728589779881818091
Hospital stay (days)228139991212297
Clinical historyAF, PD, NIDDMHTN, HTHTN, PD, HCL, MPDCoronary artery diseaseCoronary artery diseaseHTNHTN, PD
FractureLeft, AO31ALeft, AO31ALeft, AO31ARight, AO31ARight, AO31ARight, AO31ARight, AO31ALeft, AO31ARight, AO31BRight, AO31B
SARS-CoV-2 quantitative RT-PCRPositivePositivePositivePositivePositivePositivePositivePositivePositivePositive
SurgeryPFNPFNPFNPFNPFNPFNPFNPFNHAHA
Postoperative blood transfusions (N)0000210221
Complications--UTI, Pericardial effusionRespiratory failure-Respiratory failure--UTIRespiratory failure
Chest X-rayPositivePositiveNegativePositivePositiveNegativePositiveNegativePositiveNegative
Mechanical ventilationNoNoNoNoNoNoNoNoNoNo
Oxygen support through Venturi mask (L/min)AdmissionNo (SaO2 94% in AA)No (SaO2 96% in AA)No (SaO2 95% in AA)No (SaO2 93% in AA)4 L/min (SaO2 94%)No (SaO2 90% in AA)No (SaO2 97% in AA)No (SaO2 96% in AA)No (SaO2 93% in AA)No (SaO2 96% in AA)
First 3 days of hospitalization6 L/min8 L/min6 L/minNo4 L/min2 L/min2 L/min2 L/min4 L/min8 L/min
Major level needed during hospitalization10 L/min8 L/min6 L/minNo6 L/min42288
DischargeNo (SaO2 96% in AA)No (SaO2 96% in AA)No (SaO2 96% in AA)-No (SaO2 96% in AA)-2 L/min (SaO2 96%)No (SaO2 96% in AA)No (SaO2 93% in AA)No (SaO2 96% in AA)
Discharge modeCOVID-19 Rehabilitation UnitCOVID-19 Rehabilitation UnitCOVID-19 Rehabilitation UnitDeathCOVID-19 Rehabilitation UnitDeathCOVID-19 Rehabilitation UnitCOVID-19 Rehabilitation UnitCOVID-19 Rehabilitation UnitCOVID-19 Rehabilitation Unit
Follow-up (days)31292318181514163935

Abbreviations: PFN proximal femoral nailing; HA hemiarthroplasty; RT-PCR real time polymerase chain reaction; AF atrial fibrillation; HTN hypertension; HT hypothyroidism; HCL hypercholesterolemia; NIDDM diabetes mellitus; PD Parkinson’s disease; MPD myeloproliferative disorder; UTI urinary tract infection; AA ambient air

Patients’ demographics, comorbidities, surgical and clinical details, respiratory parameters and need of oxygen support Abbreviations: PFN proximal femoral nailing; HA hemiarthroplasty; RT-PCR real time polymerase chain reaction; AF atrial fibrillation; HTN hypertension; HT hypothyroidism; HCL hypercholesterolemia; NIDDM diabetes mellitus; PD Parkinson’s disease; MPD myeloproliferative disorder; UTI urinary tract infection; AA ambient air Our patients exhibited the lowest death rate (20%) to date, but, given the heterogeneous data reported by the other two case series, and the missing individual patient data of the multicentric study, the reasons for this favourable finding are unclear. In our centre, surgery for proximal femur fractures in the elderly is performed within 48 h from admission in more than 95% of patients, and this was the case for all COVID-19 patients. Two of the three operated patients reported by Mi et al. received surgery 5, 2 and 3 days after admission [10]. Catellani et al. reported surgery within 24 h after admission for 10 patients, whilst in three cases, it was postponed for haemorrhagic risk as the patients were using anticoagulant drugs [11]. Muñoz-Vives reported a mean delay from admission to surgery of 2.4 days (range 0-13) [12]. Secondly, an internal protocol, based on the previously published evidence of microvascular pulmonary thrombosis in patients with COVID-19, established the administration of low molecular weight heparin, doubling the prophylactic dose (enoxaparin sodium 4000 U.I. twice daily), as the nasopharyngeal swab showed positivity for SARS-CoV-2 [14]. The thromboembolic prophylactic therapy, if administered, was not reported by Mi and Muñoz-Vives, whilst Catellani et al. do not specify the dosage they used [10-12]. Finally, the presence of different SARS-CoV-2 clusters may explain the differences with the Chinese and Spanish studies, but it is unlikely that the viral type differed between Milan and Bergamo, two cities 60 km apart [15]. Furthermore, we retrospectively analysed the evolution of their laboratory parameters at admission, 1st and 5th ± 2 postoperative days (POD1 and POD 5 ± 2) performing a univariate repeated measures ANOVA with Greenhouse-Geisser correction and post hoc tests using the Bonferroni adjustment (statistical significance set at p ≤ 0.05; F statistic reported as F(degrees of freedomtime, degrees of freedomerror) = F value, p value). Single-patients laboratory parameters are available online as Additional file 1. Our patients demonstrated a significant reduction in leukocyte and neutrophils count and an increase in lymphocyte relative count (Table 2) comparing POD1 and POD 5 ± 2, possibly explained by the time from surgery and by the COVID-19 infection resolution, with an improvement of the peculiar SARS-CoV-2-related lymphopenia [16]. This is a noteworthy finding, considering that a low lymphocyte percentage has been considered a negative prognostic factor for COVID-19 [17].
Table 2

Comparison of patients’ mean laboratory parameters at admission and postoperative days 1 and 5 ± 2

Laboratory parametersMean value ± SD at D0Mean value ± SD at POD 1Mean value ± SD at POD 5 ± 2Post hoc test (p value)F statistic (ANOVA)
Leucocyte count (× 103/mL)10.42 ± 3.410.46 ± 2.88.65 ± 3.1

D0 vs POD1: p = 1

POD1 vs 5 ± 2: p = 0.045

F(1.585, 14.261) = 5.644, p = 0.02
Absolute neutrophil count (× 103/mL)8.46 ± 2.98.46 ± 2.46.49 ± 2.6

D0 vs POD1: p = 1

POD1 vs 5 ± 2: p = 0.026

F(1.849, 16.645) = 6.733, p = 0.008
Relative lymphocyte count (%)11.4 ± 3.211.2 ± 5.916.3 ± 6.1

D0 vs POD1: p = 1

POD1 vs 5 ± 2: p = 0.02

F(1.602, 14.420) = 5.611, p = 0.02

Univariate repeated measures ANOVA with Greenhouse-Geisser correction and post hoc tests using the Bonferroni adjustment (statistical significance set at p ≤ 0.05)

F statistic reported as F(degrees of freedomtime, degrees of freedomerror) = F value, p value)

Only significant outcomes are reported in this table

Abbreviations: D0 admission day, SD standard deviation, POD postoperative day

Comparison of patients’ mean laboratory parameters at admission and postoperative days 1 and 5 ± 2 D0 vs POD1: p = 1 POD1 vs 5 ± 2: p = 0.045 D0 vs POD1: p = 1 POD1 vs 5 ± 2: p = 0.026 D0 vs POD1: p = 1 POD1 vs 5 ± 2: p = 0.02 Univariate repeated measures ANOVA with Greenhouse-Geisser correction and post hoc tests using the Bonferroni adjustment (statistical significance set at p ≤ 0.05) F statistic reported as F(degrees of freedomtime, degrees of freedomerror) = F value, p value) Only significant outcomes are reported in this table Abbreviations: D0 admission day, SD standard deviation, POD postoperative day The beneficial effects of early standard surgical care for proximal femoral fractures in the elderly seem to be confirmed also in COVID-19 patients. In-hospital management of fracture-related and cytokine-induced musculoskeletal pain in COVID-19 patients should take into account the recent warnings about the use of common NSAIDs in case of SARS-CoV-2 infection [18-20]. Nevertheless, the mortality after proximal femur fractures remains high, especially during the first year after the fracture, and COVID-19 needs a very long time for viral clearance [21, 22]. The contribution of surgery to improve respiratory and laboratory values in COVID-19 patients with femur fractures should be verified by further studies with a longer follow-up and with control groups. Additional file 1. Laboratory values during hospitalization.
  16 in total

1.  Fracture and Dislocation Classification Compendium-2018

Authors:  Eric G Meinberg; Julie Agel; Craig S Roberts; Matthew D Karam; James F Kellam
Journal:  J Orthop Trauma       Date:  2018-01       Impact factor: 2.512

2.  Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis.

Authors:  Fabio Ciceri; Luigi Beretta; Anna Mara Scandroglio; Sergio Colombo; Giovanni Landoni; Annalisa Ruggeri; Jacopo Peccatori; Armando D'Angelo; Francesco De Cobelli; Patrizia Rovere-Querini; Moreno Tresoldi; Lorenzo Dagna; Alberto Zangrillo
Journal:  Crit Care Resusc       Date:  2020-04-15       Impact factor: 2.159

3.  Musculoskeletal symptoms in SARS-CoV-2 (COVID-19) patients.

Authors:  Lucio Cipollaro; Lorenzo Giordano; Johnny Padulo; Francesco Oliva; Nicola Maffulli
Journal:  J Orthop Surg Res       Date:  2020-05-18       Impact factor: 2.359

4.  Postoperative mortality after a hip fracture over a 15-year period in Denmark: a national register study.

Authors:  Ossian Gundel; Lau Caspar Thygesen; Ismail Gögenur; Sarah Ekeloef
Journal:  Acta Orthop       Date:  2019-10-22       Impact factor: 3.717

5.  Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.

Authors: 
Journal:  Lancet       Date:  2020-02-09       Impact factor: 79.321

6.  Emerging genetic diversity among clinical isolates of SARS-CoV-2: Lessons for today.

Authors:  Javaid Ahmad Sheikh; Jasdeep Singh; Hina Singh; Salma Jamal; Mohd Khubaib; Sunil Kohli; Ulrich Dobrindt; Syed Asad Rahman; Nasreen Zafar Ehtesham; Seyed Ehtesham Hasnain
Journal:  Infect Genet Evol       Date:  2020-04-24       Impact factor: 3.342

7.  The Italian USL Toscana Centro model of a vascular hub responding to the COVID-19 emergency.

Authors:  Emiliano Chisci; Fabrizio Masciello; Stefano Michelagnoli
Journal:  J Vasc Surg       Date:  2020-04-16       Impact factor: 4.268

8.  Treatment of Proximal Femoral Fragility Fractures in Patients with COVID-19 During the SARS-CoV-2 Outbreak in Northern Italy.

Authors:  Francesco Catellani; Andrea Coscione; Riccardo D'Ambrosi; Luca Usai; Claudio Roscitano; Gennaro Fiorentino
Journal:  J Bone Joint Surg Am       Date:  2020-06-17       Impact factor: 6.558

9.  Characteristics and Early Prognosis of COVID-19 Infection in Fracture Patients.

Authors:  Bobin Mi; Lang Chen; Yuan Xiong; Hang Xue; Wu Zhou; Guohui Liu
Journal:  J Bone Joint Surg Am       Date:  2020-05-06       Impact factor: 5.284

10.  Persistent viral RNA positivity during the recovery period of a patient with SARS-CoV-2 infection.

Authors:  Jian-Rong Yang; Dao-Ting Deng; Nan Wu; Bin Yang; Hong-Juan Li; Xiao-Ben Pan
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

View more
  9 in total

1.  COVID-19 Elderly Patients Treated for Proximal Femoral Fractures during the Second Wave of Pandemic in Italy and Iran: A Comparison between Two Countries.

Authors:  Riccardo Giorgino; Erfan Soroush; Sajjad Soroush; Sara Malakouti; Haniyeh Salari; Valeria Vismara; Filippo Migliorini; Riccardo Accetta; Laura Mangiavini
Journal:  Medicina (Kaunas)       Date:  2022-06-09       Impact factor: 2.948

2.  Meta-analysis and metaregression of risk factors associated with mortality in hip fracture patients during the COVID-19 pandemic.

Authors:  Firas J Raheman; Djamila M Rojoa; Jvalant Nayan Parekh; Reshid Berber; Robert Ashford
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

3.  Delayed hospital admission for traumatic hip fractures during the COVID-19 pandemic.

Authors:  Stephanie Jarvis; Kristin Salottolo; Robert Madayag; Jennifer Pekarek; Nnamdi Nwafo; Alexander Wessel; Therese Duane; Zachary Roberts; Mark Lieser; Chad Corrigan; David Bar-Or
Journal:  J Orthop Surg Res       Date:  2021-04-01       Impact factor: 2.359

4.  Mortality escalates in patients of proximal femoral fractures with COVID-19: A systematic review and meta-analysis of 35 studies on 4255 patients.

Authors:  Mohit Kumar Patralekh; Vijay Kumar Jain; Karthikeyan P Iyengar; Gaurav Kumar Upadhyaya; Raju Vaishya
Journal:  J Clin Orthop Trauma       Date:  2021-04-20

5.  Early mortality in hip fracture patients admitted during first wave of the COVID-19 pandemic in Northern Italy: a multicentre study.

Authors:  Dante Dallari; Luigi Zagra; Pietro Cimatti; Nicola Guindani; Rocco D'Apolito; Federico Bove; Alessandro Casiraghi; Fabio Catani; Fabio D'Angelo; Massimo Franceschini; Alessandro Massè; Alberto Momoli; Mario Mosconi; Flavio Ravasi; Fabrizio Rivera; Giovanni Zatti; Claudio Carlo Castelli
Journal:  J Orthop Traumatol       Date:  2021-04-05

6.  IMPACT-Global Hip Fracture Audit: Nosocomial infection, risk prediction and prognostication, minimum reporting standards and global collaborative audit: Lessons from an international multicentre study of 7,090 patients conducted in 14 nations during the COVID-19 pandemic.

Authors:  Andrew J Hall; Nicholas D Clement; Cristina Ojeda-Thies; Alasdair Mj MacLullich; Giuseppe Toro; Antony Johansen; Tim O White; Andrew D Duckworth
Journal:  Surgeon       Date:  2022-03-28       Impact factor: 2.632

7.  The psychological impact on an orthopaedic outpatient setting in the early phase of the COVID-19 pandemic: a cross-sectional study.

Authors:  Khai Cheong Wong; Xinyun Audrey Han; Kae Sian Tay; Suang Bee Koh; Tet Sen Howe
Journal:  J Orthop Surg Res       Date:  2020-08-12       Impact factor: 2.359

8.  The prevalence, mortality, and associated risk factors for developing COVID-19 in hip fracture patients: a systematic review and meta-analysis.

Authors:  Nicholas D Clement; Nathan Ng; Cameron J Simpson; Robyn F L Patton; Andrew James Hall; A Hamish R W Simpson; Andrew D Duckworth
Journal:  Bone Joint Res       Date:  2020-12       Impact factor: 4.410

9.  Exposure risk of patients with chronic infectious wounds during the COVID-19 outbreak and its countermeasures.

Authors:  Haiying Zhou; Qianjun Jin; Hui Lu
Journal:  J Orthop Surg Res       Date:  2020-10-02       Impact factor: 2.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.